1 / 15

Clinical Monitoring

CROMS. NIDCR. C linical Research Operations and Management Support Rho, Inc., Federal Division. National Institute of Dental and Craniofacial Research National Institutes of Health. Clinical Monitoring. Clinical Monitoring.

lark
Download Presentation

Clinical Monitoring

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CROMS NIDCR Clinical Research Operations and Management Support Rho, Inc., Federal Division National Institute of Dental and Craniofacial Research National Institutes of Health Clinical Monitoring 2012-06-07

  2. Clinical Monitoring • The monitor/CRA will review study documents to confirm adherence to: • Good Clinical Practice (GCP) • Data integrity • Informed consent • Study protocol • All other applicable regulations 2012-06-07

  3. On-Site Visits • 3 types of visits will be conducted by the CRA: • Interim monitoring • For-cause monitoring • Close-out 2012-06-07

  4. Visit Scheduling Rho CRA schedules the visit with the study team. Visit confirmation letter and agenda will be provided to the site approximately 2 weeks before visit. Visit schedule and level of monitoring is outlined in the approved Clinical Monitoring Plan (CMP). Timing and frequency of visits are based on several factors, including: level of risk, intervention, and enrollment 2012-06-07

  5. Visit Requirements • During on-site visits, the CRA will need access to the following: • Work space • Investigator site file (including access to ISF documents maintained electronically, if applicable) • Research records (paper and electronic) • All original, signed consent forms 2012-06-07

  6. Interim Monitoring Visit Activities • Consent form review • Original documents • Percentage to be reviewed is outlined in CMP • Documentation of consent process in chart • Chart review/source verification • The number of charts and percentage of data in each chart to be reviewed is addressed in the CMP • Investigator site file review • Serious Adverse Events, Unanticipated Problems • Protocol Deviations 2012-06-07

  7. Consent Form Review • Obtained prior to initiation of study procedures • Process documented in source • Date and time • Version reviewed • Study personnel conducting the discussion(s) • Topics discussed with subject • Adequate time for review of consent and questions • Subject received copy of consent • Valid signatures and dates • Correct version signed, including updates 2012-06-07

  8. Source Documentation and Data Collection Form Review The CRA will verify: Accurate, complete, and current source documentation is being maintained Subject eligibility Completion of protocol-specified procedures Proper documentation and reporting of UPs/SAEs in the source and data collection forms Accuracy of data recorded on data collection forms 2012-06-07

  9. Investigator Site File Review Verify and review all required essential documents Verify all documents are current and expired documents are replaced, with maintenance of previous versions Review Delegation of Responsibilities Log to ensure it is current and includes all site staff with signatures and appropriate study responsibilities Review Training Logs Sign Monitoring Visit Log for each day of the visit 2012-06-07

  10. Unanticipated Problems/Serious Adverse Events The CRA will: Follow-up on previously reported UPs/SAEs Verify all newly reported events against source documentation Identify unreported events recorded in source documentation Confirm events reported to IRB and as outlined in the protocol 2012-06-07

  11. Protocol Deviations The CRA will: Identify potential deviations for discussion with study team Verify that deviations are documented in source Verify deviations were reported to the IRB Address deviations with site personnel and establish plans to prevent future occurrence 2012-06-07

  12. For-Cause Visit Activities May include: Activities generally conducted during a regularly scheduled monitoring visit Discussion and review of site operations and study management Training/re-training, as appropriate 2012-06-07

  13. Close-Out Visit Activities Will include: Final consent form review Verification of required essential documents Completion of data review and source verification Confirmation of UP/SAE reporting in data collection forms and IRB Confirm that all lab samples have been shipped and appropriately stored Close-out with IRB Confirm location of study record storage and ensure PI is aware of applicable record retention policies. 2012-06-07

  14. Monitoring Visit Follow-Up Activities The CRA will: Review visit findings and help develop an action plan if needed Answer questions Depending on the study, send a visit report and action item tracker, or a follow-up letter and action item tracker Work with the study team to schedule a teleconference approximately 4-6 weeks after completion of visit to follow-up on outstanding action items 2012-06-07

  15. Contact Information • Lauren McGurk, Senior CRA • Ph: 919-595-6858 • Email: lauren_mcgurk@rhoworld.com 2012-06-07

More Related